MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases

Sara De Iudicibus, Marianna Lucafò, Stefano Martelossi, Chiara Pierobon, Alessandro Ventura, Giuliana Decorti

Research output: Contribution to journalArticle

Abstract

In spite of the introduction in therapy of highly effective biological agents, glucocorticoids (GCs) are still employed to induce remission in moderate to severe inflammatory bowel diseases (IBD), but considerable inter-individual differences in their efficacy and side effects have been reported. The effectiveness of these drugs is indeed very variable and side effects, particularly severe in pediatric patients, are common and often unpredictable: The understanding of the complex gene regulation mediated by GCs could shed light on the causes of this variability. In this context, microRNAs (miRNAs) represent a new and promising field of research. miRNAs are small non-coding RNA molecules that suppress gene expression at post-transcriptional level, and are fine-tuning regulators of diverse biological processes, including the development and function of the immune system, apoptosis, metabolism and inflammation. Emerging data have implicated the deregulated expression of certain miRNA networks in the pathogenesis of autoimmune and inflammatory diseases, such as IBD. There is a great interest in the identification of the role of miRNAs in the modulation of pharmacological response; however, the association between miRNA and GC response in patients with IBD has not yet been evaluated in a prospective clinical study. The identification of miRNAs differently expressed as a consequence of GC treatment in comparison to diagnosis, represents an important innovative approach that could be translated into clinical practice. In this review we highlight the altered regulation of proteins involved in GC molecular mechanism by miRNAs, and their potential role as molecular markers useful for predicting in advance GC response.

Original languageEnglish
Pages (from-to)7947-7954
Number of pages8
JournalWorld Journal of Gastroenterology
Volume19
Issue number44
DOIs
Publication statusPublished - Nov 28 2013

Fingerprint

MicroRNAs
Inflammatory Bowel Diseases
Glucocorticoids
Biological Phenomena
Small Untranslated RNA
Biological Factors
Individuality
Autoimmune Diseases
Immune System
Prospective Studies
Pharmacology
Pediatrics
Apoptosis
Inflammation
Gene Expression
Therapeutics
Research
Pharmaceutical Preparations
Genes
Proteins

Keywords

  • Glucocorticoids
  • Inflammatory bowel diseases
  • MicroRNA
  • Molecular markers
  • Pharmacogenomics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. / De Iudicibus, Sara; Lucafò, Marianna; Martelossi, Stefano; Pierobon, Chiara; Ventura, Alessandro; Decorti, Giuliana.

In: World Journal of Gastroenterology, Vol. 19, No. 44, 28.11.2013, p. 7947-7954.

Research output: Contribution to journalArticle

De Iudicibus, Sara ; Lucafò, Marianna ; Martelossi, Stefano ; Pierobon, Chiara ; Ventura, Alessandro ; Decorti, Giuliana. / MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. In: World Journal of Gastroenterology. 2013 ; Vol. 19, No. 44. pp. 7947-7954.
@article{67976ce61c3a4494844f2cde1f7c8930,
title = "MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases",
abstract = "In spite of the introduction in therapy of highly effective biological agents, glucocorticoids (GCs) are still employed to induce remission in moderate to severe inflammatory bowel diseases (IBD), but considerable inter-individual differences in their efficacy and side effects have been reported. The effectiveness of these drugs is indeed very variable and side effects, particularly severe in pediatric patients, are common and often unpredictable: The understanding of the complex gene regulation mediated by GCs could shed light on the causes of this variability. In this context, microRNAs (miRNAs) represent a new and promising field of research. miRNAs are small non-coding RNA molecules that suppress gene expression at post-transcriptional level, and are fine-tuning regulators of diverse biological processes, including the development and function of the immune system, apoptosis, metabolism and inflammation. Emerging data have implicated the deregulated expression of certain miRNA networks in the pathogenesis of autoimmune and inflammatory diseases, such as IBD. There is a great interest in the identification of the role of miRNAs in the modulation of pharmacological response; however, the association between miRNA and GC response in patients with IBD has not yet been evaluated in a prospective clinical study. The identification of miRNAs differently expressed as a consequence of GC treatment in comparison to diagnosis, represents an important innovative approach that could be translated into clinical practice. In this review we highlight the altered regulation of proteins involved in GC molecular mechanism by miRNAs, and their potential role as molecular markers useful for predicting in advance GC response.",
keywords = "Glucocorticoids, Inflammatory bowel diseases, MicroRNA, Molecular markers, Pharmacogenomics",
author = "{De Iudicibus}, Sara and Marianna Lucaf{\`o} and Stefano Martelossi and Chiara Pierobon and Alessandro Ventura and Giuliana Decorti",
year = "2013",
month = "11",
day = "28",
doi = "10.3748/wjg.v19.i44.7947",
language = "English",
volume = "19",
pages = "7947--7954",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "44",

}

TY - JOUR

T1 - MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases

AU - De Iudicibus, Sara

AU - Lucafò, Marianna

AU - Martelossi, Stefano

AU - Pierobon, Chiara

AU - Ventura, Alessandro

AU - Decorti, Giuliana

PY - 2013/11/28

Y1 - 2013/11/28

N2 - In spite of the introduction in therapy of highly effective biological agents, glucocorticoids (GCs) are still employed to induce remission in moderate to severe inflammatory bowel diseases (IBD), but considerable inter-individual differences in their efficacy and side effects have been reported. The effectiveness of these drugs is indeed very variable and side effects, particularly severe in pediatric patients, are common and often unpredictable: The understanding of the complex gene regulation mediated by GCs could shed light on the causes of this variability. In this context, microRNAs (miRNAs) represent a new and promising field of research. miRNAs are small non-coding RNA molecules that suppress gene expression at post-transcriptional level, and are fine-tuning regulators of diverse biological processes, including the development and function of the immune system, apoptosis, metabolism and inflammation. Emerging data have implicated the deregulated expression of certain miRNA networks in the pathogenesis of autoimmune and inflammatory diseases, such as IBD. There is a great interest in the identification of the role of miRNAs in the modulation of pharmacological response; however, the association between miRNA and GC response in patients with IBD has not yet been evaluated in a prospective clinical study. The identification of miRNAs differently expressed as a consequence of GC treatment in comparison to diagnosis, represents an important innovative approach that could be translated into clinical practice. In this review we highlight the altered regulation of proteins involved in GC molecular mechanism by miRNAs, and their potential role as molecular markers useful for predicting in advance GC response.

AB - In spite of the introduction in therapy of highly effective biological agents, glucocorticoids (GCs) are still employed to induce remission in moderate to severe inflammatory bowel diseases (IBD), but considerable inter-individual differences in their efficacy and side effects have been reported. The effectiveness of these drugs is indeed very variable and side effects, particularly severe in pediatric patients, are common and often unpredictable: The understanding of the complex gene regulation mediated by GCs could shed light on the causes of this variability. In this context, microRNAs (miRNAs) represent a new and promising field of research. miRNAs are small non-coding RNA molecules that suppress gene expression at post-transcriptional level, and are fine-tuning regulators of diverse biological processes, including the development and function of the immune system, apoptosis, metabolism and inflammation. Emerging data have implicated the deregulated expression of certain miRNA networks in the pathogenesis of autoimmune and inflammatory diseases, such as IBD. There is a great interest in the identification of the role of miRNAs in the modulation of pharmacological response; however, the association between miRNA and GC response in patients with IBD has not yet been evaluated in a prospective clinical study. The identification of miRNAs differently expressed as a consequence of GC treatment in comparison to diagnosis, represents an important innovative approach that could be translated into clinical practice. In this review we highlight the altered regulation of proteins involved in GC molecular mechanism by miRNAs, and their potential role as molecular markers useful for predicting in advance GC response.

KW - Glucocorticoids

KW - Inflammatory bowel diseases

KW - MicroRNA

KW - Molecular markers

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84888617067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888617067&partnerID=8YFLogxK

U2 - 10.3748/wjg.v19.i44.7947

DO - 10.3748/wjg.v19.i44.7947

M3 - Article

C2 - 24307788

AN - SCOPUS:84888617067

VL - 19

SP - 7947

EP - 7954

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 44

ER -